Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on LTR Pharma.
RELATED STOCKHEAD STORIES
News
Closing Bell: Iron ore miners hammered, but Trump’s Canada tariffs boost uranium stocks
Health & Biotech
Health Check: We’ll see you in court and you bladder believe it, says Pacific Edge after unfavourable US ruling
Health & Biotech
LTR Pharma inks deal with men’s health provider for ED therapy
Health & Biotech
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
Stockhead TV
Break it Down: Quick access to quick ED fix from LTR Pharma
Health & Biotech
LTR Pharma successfully completes $25m cap raise to accelerate novel ED treatment
Health & Biotech
Health Check: The robots are taking over biotech stock selection
Health & Biotech
Renerve all set to become only the second nerve-repair stock on the ASX
Health & Biotech
LTR Pharma joins with leading men’s health group to launch telehealth platform
Health & Biotech
Health Check: It’s a small world after all for global microcap index additions LTR Pharma and EZZ Life Science
Health & Biotech
ASX Quarterly Health Wrap: Lift-off for ED nasal spray and record users for pregnancy-monitoring platform
Health & Biotech
LTR Pharma’s ED treatment SPONTAN outperforms with 470% faster absorption
Health & Biotech
Health Check: Thirsty Chimeric goes to the well for funding top-up
Health & Biotech
ASX stocks leading clinical trials in Australia
Health & Biotech
Bio Curious: Nerve repair house plans to break the IPO drought
Health & Biotech
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
News